Back to Search
Start Over
Correction to: Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents—a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group
- Source :
- Ann Hematol
- Publication Year :
- 2021
- Publisher :
- Springer Berlin Heidelberg, 2021.
-
Abstract
- Treatment of relapse after allogeneic hematopoietic stem cell transplantation (alloHSCT) remains a great challenge. Aiming to evaluate the combination of venetoclax and hypomethylating agents (HMAClax) for the treatment of relapse of myeloid malignancies after alloHSCT, we retrospectively collected data from 32 patients treated at 11 German centers. Venetoclax was applied with azacitidine (n = 13) or decitabine (n = 19); 11 patients received DLI in addition. HMAClax was the first salvage therapy in 8 patients. The median number of cycles per patient was 2 (1-19). All but 1 patient had grade 3/4 neutropenia. Hospital admission for grade 3/4 infections was necessary in 23 patients (72%); 5 of these were fatal. In 30 evaluable patients, overall response rate (ORR) was 47% (14/30, 3 CR MRD
- Subjects :
- Salvage Therapy
Sulfonamides
Transplantation Conditioning
Hematopoietic Stem Cell Transplantation
Correction
Kaplan-Meier Estimate
DNA Methylation
Allografts
Bridged Bicyclo Compounds, Heterocyclic
Decitabine
Combined Modality Therapy
Thrombocytopenia
Leukemia, Myeloid, Acute
Leukocyte Count
Recurrence
Germany
Myelodysplastic Syndromes
Antineoplastic Combined Chemotherapy Protocols
Azacitidine
Drug Evaluation
Humans
Tumor Lysis Syndrome
Immunosuppressive Agents
Febrile Neutropenia
Retrospective Studies
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Journal :
- Ann Hematol
- Accession number :
- edsair.pmid..........878dc598c1b7e40188e2a5a1b33cf2a6